Navigation Links
Global Biopharmaceutical Leader in Peptide Research Expands Commitment in San Diego/U.S. With New R&D Facility and Ready-To-Market Prostate Cancer Treatment Degarelix
Date:2/11/2009

apies."

Ferring Research Institute's translational research model--which involves collaboration with top academic and researchers from throughout the U.S. and globally--has resulted in the discovery of a number of new chemical entities now at various stages of regulatory review and clinical development.

The new San Diego research facility now houses expanded research laboratories for peptide medicinal chemistry, bioanalytical and DMPK (distribution, metabolism and Pharmacokinetics), molecular and cell biology, cell culture, in vitro and in vivo pharmacology.

About Ferring Pharmaceuticals, Inc.

Ferring Pharmaceuticals, Inc. is a subsidiary of Ferring Pharmaceuticals, a privately owned, international pharmaceutical company. Ferring Pharmaceuticals offers a line of urology, orthopaedic and infertility products in the U.S. market. They include: EUFLEXXA(R), (1% sodium hyaluronic acid), BRAVELLE(R) (urofollitropin for injection, purified), MENOPUR(R) and REPRONEX(R) (menotropins for injection, USP), NOVAREL(R) (chorionic gonadotropin for injection, USP), ENDOMETRIN(R) (progesterone) Vaginal Insert, ACTHREL(R) (corticorelin ovine triflutate for injection), PROSED(R) DS (methenamine, phenyl salicylate, methylene blue, benzoic acid, hyoscyamine sulfate), and DESMOPRESSIN. Ferring Pharmaceuticals specializes in the research, development and commercialization of compounds in general and pediatric endocrinology, urology, orthopaedics, gastroenterology, obstetrics/gynecology and infertility. More information is available at www.ferring.com.

About Ferring Research Institute, Inc.

Ferring Research Institute, Inc. was founded in 1996 by Ferring Pharmaceuticals as a center for peptide research. Located in San Diego the Institute's peptide technology focuses on naturally-occurring peptides, hormones and receptors which control th
'/>"/>

SOURCE Ferring Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Global Experts Explore Entire Spectrum of Aids Vaccine Development
2. Mindray to Present at Merrill Lynch Global Pharmaceutical, Biotech & Medtech Conference
3. Advanced Life Sciences to Present at 2007 UBS Global Life Sciences Conference
4. Touching 418 Billion Lives, Hepatitis Still Presents Significant Threat to Global Health
5. Touching 418 Million Lives, Hepatitis Still Presents Significant Threat to Global Health
6. Clinsys Clinical Research, Inc. Announces Key Hires, Rajagopalan Srinivasan, Ph.D, to Strengthen Global Biostatistics Service Offering and Christopher Gregory, Ph.D, to Scientific Affairs
7. Jazz Pharmaceuticals to Present at UBS Global Life Sciences Conference
8. A Large-Scale Research Project by a Dutch Consortium Addressing a Global Problem
9. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotech & Medtech 2007 Conference
10. Allos Therapeutics to Present at the 2007 UBS Global Life Sciences Conference
11. Merrill Lynch Global Pharmaceutical, Biotech and Medtech Conference to Webcast Millennium Presentation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... 20, 2014 Mapp Biopharmaceutical,s valiant effort ... therapeutic to fight the Ebola outbreak will make ... the production of pharmaceuticals can be, according to ... that while some may be taken aback by ... with industry knowledge are well aware of the ...
(Date:10/20/2014)... 2014 Asterias Biotherapeutics, Inc. (NYSE MKT: ... a Notice of Grant Award (NGA) with the ... 1, 2014.  The NGA provides for the immediate ... of additional grant funds pursuant to the previously ... development of Asterias, product, AST-OPC1. The grant provides ...
(Date:10/20/2014)... , October 20, 2014 , ... (GI) disorders and the delivery of care has revealed ... and worrying inequalities in the provision of healthcare services ... was commissioned by United European Gastroenterology (UEG), have been ... and public awareness of the burden of GI disorders ...
(Date:10/20/2014)... , Oct. 20, 2014 PureTech ... company tackling big healthcare problems, announced today the ... round, with participation from Invesco Perpetual, a $120 ... used to drive PureTech,s existing pipeline forward and ... "PureTech has the scientific creativity to really go ...
Breaking Biology Technology:Kalorama: ZMapp Highlights Need For Faster Biopharmaceutical Production 2Kalorama: ZMapp Highlights Need For Faster Biopharmaceutical Production 3Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 2Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 3Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 4Major Survey Reveals Changing Trends and Inequalities in Healthcare Provision for Gastrointestinal Disorders Across Europe 2Major Survey Reveals Changing Trends and Inequalities in Healthcare Provision for Gastrointestinal Disorders Across Europe 3Major Survey Reveals Changing Trends and Inequalities in Healthcare Provision for Gastrointestinal Disorders Across Europe 4Major Survey Reveals Changing Trends and Inequalities in Healthcare Provision for Gastrointestinal Disorders Across Europe 5PureTech Announces Expansion with Oversubscribed $55M Funding Round 2PureTech Announces Expansion with Oversubscribed $55M Funding Round 3PureTech Announces Expansion with Oversubscribed $55M Funding Round 4PureTech Announces Expansion with Oversubscribed $55M Funding Round 5PureTech Announces Expansion with Oversubscribed $55M Funding Round 6
... /PRNewswire-FirstCall/ - Victhom Human Bionics Inc., "Victhom" (TSX:VHB), ... CE Mark approval for its Neurostep(TM) System, the ... used on peripheral nerves. CE Mark represents regulatory ... in any of the Member States of the ...
... NOVATO, Calif., Feb. 3 BioMarin Pharmaceutical Inc. (Nasdaq: ... National Health Surveillance Agency, has granted BioMarin marketing approval ... Mucopolysaccharidosis VI (MPS VI)."We are very pleased to receive ... largest known number of affected MPS VI patients in ...
... 3 Poniard,Pharmaceuticals, Inc. (Nasdaq: PARD ), ... that Jerry McMahon, Ph.D.,chairman and CEO, will present at ... Tuesday, February 10, at 10 a.m. Eastern Time at ... Dr. McMahon will provide a corporate overview, including a ...
Cached Biology Technology:Victhom Human Bionics Receives CE Mark for the Neurostep(TM) System, the World's First Fully Implantable Closed-Loop Neuromodulation Therapy for Treatment of Foot Drop 2Victhom Human Bionics Receives CE Mark for the Neurostep(TM) System, the World's First Fully Implantable Closed-Loop Neuromodulation Therapy for Treatment of Foot Drop 3Naglazyme Approved by Brazil's National Health Surveillance Agency 2Naglazyme Approved by Brazil's National Health Surveillance Agency 3Naglazyme Approved by Brazil's National Health Surveillance Agency 4Poniard Pharmaceuticals to Present at the BIO CEO & Investor Conference 2
(Date:10/14/2014)... shows SIRT6—a protein known to inhibit the growth ... skin cancers by turning on an enzyme that increases ... Previously considered protective, SIRT6 is part of a family ... stability and prevent some of the genetic flaws associated ... lead to cancer. This study, in the journal,s October ...
(Date:10/14/2014)... to produce enough food to feed the world in ... of the United Nations predicts that food production must ... a growing global population, and plants are one major ... Plants—grains, cereals, fruits, vegetables, and more—feed humans directly and ... into our knowledge of how plants work to develop ...
(Date:10/14/2014)... LA JOLLA, CA – October 14, 2014 – Scientists ... $6.6 million from the National Institutes of Health (NIH) ... most prevalent virus-induced hemorrhagic fever disease in Africa. The ... disease and why some patients die, while others survive ... researchers to understand the basic mechanism of how Lassa ...
Breaking Biology News(10 mins):Two-faced gene: SIRT6 prevents some cancers but promotes sun-induced skin cancer 2Building a bridge from basic botany to applied agriculture 2Building a bridge from basic botany to applied agriculture 3Scripps Research Institute team receives $6.6 million to investigate deadly Lassa virus 2
... the possibility that the critically short supply of livers ... "marginal" livers with a substance that protects them from ... report appears in ACS, journal Molecular Pharmaceutics . ... for liver transplants has grown over the years, though ...
... DALLAS June 1, 2011 A drug ... as a therapy for a common form of dementia, ... hydroxamic acid (SAHA) holds promise as a first-generation drug ... (FTD), a progressive, inherited neurodegenerative disease for which there ...
... Virginia Tech,s Advanced Experimental Thermofluid Engineering Research ... professor Pavlos P. Vlachos, professor of mechanical engineering, ... mechanics from the Measurement Science and Technology ... Physics. John J. Charonko, of Blacksburg, ...
Cached Biology News:Cancer drug holds promise as first treatment for common, inherited dementia 2Virginia Tech mechanical engineers win measurement science best paper award 2